The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

West Pharmaceutical Q2'24 results missed expectations, with lower revenues and EPS missing guidance, impacted by destocking and poor sales in various segments. Management remains optimistic for the back half of the year, with capital investments to support growth, but cash flow concerns and high valuation pose risks. Despite the recent drop in WST share price, the company's high valuation and uncertain cash flow outlook make it unattractive for investment at this time.

West Pharmaceutical's (WST) second-quarter results reflect a declining demand for products across its segments amid elevated customer destocking.

West Pharmaceutical Services (WST) came out with quarterly earnings of $1.52 per share, missing the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.11 per share a year ago.

West Pharmaceutical Services cut its annual profit and sales forecast on Thursday, on lower demand for its medical equipment used in making injectable drugs as biotech customers worked through their existing inventories.

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

Stocks outperform cash, but most wealth comes from a few standout companies. More than half of individual stocks lose money long-term, highlighting the need for careful selection. Investors can build wealth with stocks offering essential products and steady growth. Success doesn't require high-risk choices but finding solid, reliable performers. The article explores three promising stocks flying under the radar, each excelling in critical industries. These picks demonstrate how strategic investments can yield impressive returns.

Barron's Mid-Year 2024 Pro Picks revealed by panelists for potential investment opportunities. Barron's interviews of eleven financial industry Roundtable-pros tapped 48 predictions. Twelve non-ADR foreign stocks and six funds were dropped by YCharts screens, and six selections paid no dividends, leaving 24 in the final pool. The Barron's list tracked by YCharts as of 7/17/24 projected ten top analyst-estimated net gains from WST, ASML, PBR, RUSHA & topped by SLB ranging 19.46%-35.09%.

West Pharmaceutical's (WST) second-quarter 2024 results are likely to reflect strength in its Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.

EXTON, Pa. , July 11, 2024 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter financial results before the market opens on Thursday, July 25, 2024, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.